Why is sodium bicarbonate prescribed in chronic kidney disease?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 9, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Why Sodium Bicarbonate is Prescribed in Chronic Kidney Disease

Sodium bicarbonate is prescribed in CKD to prevent and treat metabolic acidosis, which slows kidney disease progression, prevents protein catabolism and muscle wasting, reduces bone demineralization, and improves survival. 1

Primary Indication: Correcting Metabolic Acidosis

  • Start oral sodium bicarbonate when serum bicarbonate falls below 22 mmol/L in CKD stages 3-5, as recommended by the National Kidney Foundation and American College of Physicians. 1, 2

  • Pharmacological treatment is strongly recommended when bicarbonate drops below 18 mmol/L to prevent severe clinical complications. 1, 3

  • The kidneys in CKD lose their ability to excrete hydrogen ions and synthesize ammonia, leading to progressive acid accumulation in the body. 3

Mechanism of Kidney Protection

  • Sodium bicarbonate therapy slows the rate of decline in kidney function, with creatinine doubling occurring in only 6.6% of bicarbonate-treated patients versus 17.0% in standard care over approximately 30 months. 1

  • In stage 4 CKD patients, bicarbonate supplementation significantly reduces the decline in eGFR compared to controls (-2.30 vs -6.58 mL/min/1.73m² over 12 months). 4

  • The protective mechanism may extend beyond simple pH correction, as some studies suggest benefit regardless of baseline acidosis severity, though the exact physiological pathways remain under investigation. 5

Prevention of Protein Catabolism and Muscle Wasting

  • Correcting acidosis prevents increased oxidation of branched-chain amino acids (valine, leucine, isoleucine), which directly correlates with plasma bicarbonate levels. 2, 3

  • Acidosis increases protein degradation rates and decreases albumin synthesis, leading to malnutrition and muscle wasting in CKD patients. 1, 2

  • Correction of metabolic acidosis improves albumin synthesis, increases serum albumin levels, and may promote greater body weight gain and increased mid-arm circumference. 2

  • In stage 5 CKD, bicarbonate supplementation significantly improves nutritional indices including total lymphocyte count and Ondodera's prognostic nutritional index. 4

Bone Health Benefits

  • Maintaining serum bicarbonate ≥22 mmol/L is associated with normal bone biopsy results, versus mixed osteodystrophy at levels <20 mmol/L. 1

  • Correcting acidosis prevents bone demineralization by reducing bone resorption, improves bone histology, and reduces secondary hyperparathyroidism progression. 1, 2

  • Chronic metabolic acidosis alters the homeostatic relationships between blood ionized calcium, PTH, and vitamin D, leading to bone dissolution to buffer excess acid. 3

Dosing Recommendations

  • The typical effective dose is 0.4-0.5 mEq/kg/day or 2-4 g/day (25-50 mEq/day) divided into 2-3 doses to normalize serum bicarbonate levels. 1, 2

  • For patients unable to tolerate commercial preparations, baking soda (1/4 teaspoon = 1 g of sodium bicarbonate) may be substituted. 1, 2

  • Target maintenance is serum bicarbonate ≥22 mmol/L but not exceeding the upper limit of normal (typically 28-29 mmol/L) to avoid metabolic alkalosis. 1, 2

Critical Monitoring Requirements

  • Serum bicarbonate should be monitored monthly initially, then at least every 3 months once stable in CKD patients on therapy. 1, 2

  • Monitor serum potassium closely, as bicarbonate therapy can decrease potassium levels and help manage hyperkalemia in patients on RAS inhibitors. 1, 6

  • Blood pressure, fluid status, and weight must be monitored regularly to detect adverse effects from sodium loading. 1

Important Contraindications and Caveats

  • Exercise caution or avoid sodium bicarbonate in patients with advanced heart failure with significant volume overload, poorly controlled hypertension, or significant edema due to the sodium load. 1, 3

  • The sodium load (approximately 1 gram of sodium per 8.4 grams of sodium bicarbonate) must be weighed against benefits, particularly in volume-sensitive states. 1, 2

  • Do not wait until bicarbonate is severely depressed (<18 mmol/L) before initiating therapy; start at <22 mmol/L to prevent complications. 1

  • Do not over-correct bicarbonate above the upper limit of normal, as this causes metabolic alkalosis. 1

Alternative Dietary Approach

  • Increasing fruit and vegetable intake reduces net acid production and may provide additional benefits beyond bicarbonate supplementation, including reduced systolic blood pressure, potential weight loss, and increased fiber intake. 1, 2

  • Fruits and vegetables provide potassium citrate salts that generate alkali, which helps buffer acids naturally. 2, 3

  • However, avoid citrate-containing alkali in CKD patients exposed to aluminum-containing phosphate binders, as citrate increases aluminum absorption and worsens bone disease. 2, 3

Special Populations

  • In children with CKD, metabolic acidosis should be corrected to serum bicarbonate ≥22 mEq/L, as correction is essential before considering growth hormone therapy to prevent growth retardation. 1, 2

  • For CKD patients developing hyperkalemia on RAS inhibitors, sodium bicarbonate can be used as part of a strategy to control potassium levels while maintaining RAS blockade. 1

Duration of Treatment

  • Sodium bicarbonate therapy should be continued indefinitely as long as CKD persists and serum bicarbonate remains <22 mmol/L without treatment. 1

  • Discontinuation should only be considered if the patient progresses to dialysis (where dialysate bicarbonate maintains levels), develops contraindications, or experiences intolerable side effects. 1

References

Guideline

Sodium Bicarbonate Therapy for Chronic Kidney Disease

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Initiation and Management of Oral Bicarbonate Therapy in Metabolic Acidosis

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Acid-Base Disorders and Bicarbonate Levels

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Research

Alkali supplementation as a therapeutic in chronic kidney disease: what mediates protection?

American journal of physiology. Renal physiology, 2020

Research

Effects of Sodium Bicarbonate in CKD Stages 3 and 4: A Randomized, Placebo-Controlled, Multicenter Clinical Trial.

American journal of kidney diseases : the official journal of the National Kidney Foundation, 2020

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.